Popular Science Honors Innovative Verisante Aura(TM)Skin Cancer Detection Device with "Best of What's New" Award
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 16, 2011) -Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(PINKSHEETS:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancerimaging technology, announced today that the editors of Popular Sciencemagazine have named Verisante's Aura™ device for skin cancer detection as atop technology innovation of 2011, receiving one of the magazine's coveted "Bestof What's New" Awards.
"For 24 years, Popular Science has honored the innovations thatsurprise and amaze us - those that make a positive impact on our world today andchallenge our views of what's possible in the future," said Mark Jannot,Editor-in-Chief of Popular Science. "The Best of What's New Award isthe magazine's top honor, and the 100 winners - chosen from among thousands ofentrants - represent the highest level of achievement in their fields."
Thomas Braun, President and CEO of Verisante Technology, Inc., said Verisanteis honored to be recognized by Popular Science as a company that ismaking revolutionary advancements in the detection of skin cancer.
"This award is a validation of the hard work and dedication of our employees,consultants, and partners who have come together to make the commercializationof this life-saving device possible," he said. "We are pleased that ourcommitment to innovation and the exceptional work done by the BC Cancer Agencyto develop the Verisante Aura™ is being internationally recognized."
Early detection is key to saving the lives of melanoma patients and savinghealthcare costs. When melanoma is diagnosed and treated in the earliest stages,the survival rate is 99 per cent and it costs about $1,800 to treat it. In thelate stages, the survival rate decreases to 15 per cent, while the cost to treatit increases to $170,000. The Aura™ will aid medical professionals in theassessment of suspect skin lesions for diagnosis as either skin cancer or abenign disorder in less than two seconds.
Verisante Aura™, a non-invasive optical system, is indicated for use for theevaluation of skin lesions that may be clinically suspicious for melanoma,squamous cell carcinoma and/or basal cell carcinoma when a medical professionalchooses to obtain additional information to rule out one of the above conditionsbefore making a final decision to biopsy.
The Popular Science issue containing the winners of the Best ofWhat's New Awards is now on sale.
About Best of What's New
Each year, the editors of Popular Science review thousands ofproducts in search of the top 100 tech innovations of the year; breakthroughproducts and technologies that represent a significant leap in their categories.The winners – the Best of What's New – are awarded inclusion in the muchanticipated
December issue of Popular Science, the most widely read issue of theyear since the debut of Best of What's New in 1987. Best of What's New Awardsare presented to 100 new products and technologies in 11 categories.
About Popular Science
Founded in 1872, Popular Science is the world's largest science andtechnology magazine; with a circulation of 1.3 million and 6.8 million monthlyreaders. Each month, Popular Science reports on the intersection ofscience and everyday life, with an eye toward what's new and why it matters. |
